KEGG   DRUG: TisagenlecleucelHelp
Entry
D11386                      Drug                                   

Name
Tisagenlecleucel (USAN/INN);
Tisagenlecleucel-T;
Kymriah (TN)
Product
Remark
Product: D11386<US>
Efficacy
Antineoplastic, Anti-CD19 CAR-T cell
  Disease
B-cell acute lymphoblastic leukemia [DS:H00001]
Comment
Cellular therapy product
Target
CD19 [HSA:930] [KO:K06465]
  Pathway
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11386  Tisagenlecleucel (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D11386
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11386
 Cellular and gene therapy products
  D11386
New drug approvals in Japan [br08318.html]
 Cellular and gene therapy products
  D11386
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11386
BRITE hierarchy
Other DBs
CAS: 1823078-37-0
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system